M&A / Deals Bayer banks 3bn in Apollo contraceptives division deal Pharmaceutical TechnologyBayer's agreement with Apollo comes a little after Bayer broke its pharma dealmaking fast by acquiring Perfuse Therapeutics in May 2026.Read full story pharminent July 10, 2026 (Last updated: July 15, 2026) Pharmaceutical Technology Bayer’s agreement with Apollo comes a little after Bayer broke its pharma dealmaking fast by acquiring Perfuse Therapeutics in May 2026. Read full story Post navigation Previous: Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilarNext: GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026